Announcement Released Sat-18th-March-2017 02:52 GMT
Contact: Administrator Account Institution: ResearchSEA
 
Exploring Quality Care for Rare Disease Patients in Asia
Business

The World Orphan Drug Congress Asia 2017, (21 March, Tuesday) is where we gather rare disease patients together with pharma drug manufacturers to discuss orphan drug access challenges and strategies in the Asia-Pacific.


1 March 2017 - Rare disease patients in the Asia-Pacific region are in dire need of orphan drugs. Fundamental problems such as physical access to orphan drugs have to be addressed properly, because patients often need to import drugs from another country. This translates to a need for the right clinician for a prescription from foreign countries.

The World Orphan Drug Congress Asia 2017, (21 March, Tuesday) is where we gather rare disease patients together with pharma drug manufacturers to discuss orphan drug access challenges and strategies in the Asia-Pacific.

The 4 key themes of this event are:

PHYSICAL ACCESS TO ORPHAN DRUGS IN ASIA
Speakers:
· John Lim, ‎Executive Director, Duke-NUS Centre of Regulatory Excellence & Chairman, Singapore Clinical Research Institute
· Wong Chien Yeh, Chief Pharmacist/Director, Alliance Pharm

INDUSTRY & IN-COUNTRY PERSPECTIVE
Speakers:
· Teik-Lee Yu, Marketing Lead (Pompe), Emerging Markets, Sanofi Aventis Singapore Pte. Ltd.
· Carolyn Anne Hall, Head of Patient Service, APAC, Shire
· Cinzia Dorigo, Executive Director, Clinical Development, INC Research
· Edmund Lim, Co-founder, We CARE Journey Malaysia

PATIENT PERSPECTIVE
Speakers:
· Carmencita Padilla, Chancellor, Department of Pediatrics, College of Medicine and Philippine General Hospital, University of the Philippines Manila
· Ravdeep Singh Anand, Founder – President, Dystrophy Annihilation Research Trust
· Edmund Lim, Co-founder, We CARE Journey Malaysia
· Kenneth Mah, Executive Director, Rare Disorders Society Singapore
· Cynthia Magdaraog, President, Philippine Society of Orphan Disorders

EARLY DIAGNOSIS
Speakers:
· Dr. Maria Melanie Liberty B. Alcuasin, Director, New Born Screening Reference Center Philippines, NIH, UP Manila
· Carmencita Padilla, Chancellor, Department of Pediatrics, College of Medicine and Philippine General Hospital, University of the Philippines Manila


For the first time, the World Orphan Drug Congress Asia will be held at Biopolis @ one-north, a vibrant, purpose-built biomedical research and development hub in Singapore, masterplanned and developed by the nation’s industrial infrastructure developer, JTC. With 13 buildings and a total floor area of more than 340,000 square metres, Biopolis is a thriving eco-system home to leading public and private biomedical research institutes such as Abbott, Procter & Gamble (P&G) as well as the Agency for Science, Technology and Research (A*STAR), Singapore’s lead agency for scientific research and development. The hosting of the World Orphan Drug Congress Asia in Biopolis will provide a valuable opportunity for networking and potential collaboration among international and local thought leaders from the biomedical community.

Biopolis is part of one-north, which boasts a unique mix of knowledge industries including science, engineering, infocomm technology, media and start-ups. The co-location of knowledge-intensive activities within a conducive environment has fostered innovation and encouraged collaboration and partnerships, making one-north an epicentre for advanced research and development and high value-added business activities.


About World Orphan Drug Congress Asia 2017

Date: 21 March 2017
Conference opening hours: 09:00 am
Venue: Biopolis @ one-north, Auditorium at Matrix
Website: http://www.terrapinn.com/conference/world-orphan-drug-congress-asia


About Terrapinn
Terrapinn is a business media company. Its products are trade exhibitions, conferences, training solutions and electronic and print publications. For more information, please visit www.terrapinn.com.


About JTC
Set up in 1968, JTC is the lead government agency responsible for the development of industrial infrastructure to support and catalyse the growth of industries and enterprises in Singapore. Landmark projects by JTC include the Jurong Industrial Estate; the Jurong Island for energy and chemical industries; business and specialised parks such as Airport Logistics Park of Singapore, International Business Park, Changi Business Park, Seletar Aerospace Park, CleanTech Park and Tuas Biomedical Park; a new work-live-play-&-learn development called one-north; and the Jurong Rock Caverns, Southeast Asia’s first commercial underground storage facility for liquid hydrocarbons. JTC also develops innovative space such as JTC Surface Engineering Hub, JTC MedTech Hub @ MedTech Park and JTC Food Hub @ Senoko, which incorporate innovative features and shared infrastructure to enable industrialists to start their operations quickly and enhance productivity.
For more information, visit www.jtc.gov.sg


Note: Press registration for the conference is compulsory and advance scheduling for speaker/ sponsor interviews is recommended. Final issuance of press passes is subjected to Terrapinn's discretion. For your press pass, please contact the following:

Mildred Ang, Marketing Manager
Tel: +65 6322 2769
mildred.ang@terrapinn.com

Sara-Jean Yip, Manager, Placemaking
Tel: +65 6883 3062
sara-jean_yip@jtc.gov.sg

Associated websites:

Create Account...